Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities maintained a Buy rating on the stock and has a €123.00 price target.
Graham Parry has given his Buy rating due to a combination of factors that highlight Sanofi’s strong financial performance and growth prospects. The company is expected to report a 13% year-over-year increase in earnings per share, driven by a 9% rise in sales, which aligns with consensus expectations. Key products like Dupixent are performing well, with a 23% year-over-year growth, and the launch of COPD treatments is anticipated to further boost sales.
Moreover, Sanofi’s pipeline is promising, with potential positive outcomes from ongoing clinical trials and new product launches, which could enhance future earnings. The company’s valuation appears attractive, with a price-to-earnings ratio that undervalues its projected earnings growth. Additionally, Sanofi’s strategic initiatives, such as share buybacks and pipeline approvals, are expected to support its financial performance, leading Parry to maintain a Buy rating on the stock.
According to TipRanks, Parry is ranked #2556 out of 9348 analysts.
In another report released on April 9, Jefferies also maintained a Buy rating on the stock with a €120.00 price target.